Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

BIOHOPE Scientific Solutions for Human Health SL is a private company headquartered in Spain. The firm develops diagnostic and therapeutic solutions for organ transplantation.

Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals. Mitsubishi Tanabe Pharma contribute to the healthier lives of people around the world through the creation of pharmaceuticals.” In accordance with this philosophy, as we implement our business activities we strive to realize our vision, which expresses that “Mitsubishi Tanabe Pharma strive to be a global research-driven pharmaceutical company that is trusted by communities.” As a company that is trusted and highly evaluated by patients and health care professionals as well as by society and shareholders, we will implement management with a focus on transparency and fairness while always keeping in mind the starting point of our business activities: “Everything we do is for the patients.”

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Vitaeris has licensed global exclusive rights to the best-in-class anti-interleukin-6 monoclonal antibody Clazakizumab from Alder Biopharmaceuticals, and is actively pursuing innovative applications in chronic inflammatory diseases.

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Hangzhou Ruipu Chenchuang Technology Co., Ltd., established on 2014-08-08, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;R&D and application of cell technology;Human stem cell technology development and application;Medical Research and Experimental Development;Development of Human Gene Diagnosis and Therapy Technology;Research and development of bio-based materials technology;Engineering and Technology Research and Experimental Development;Health Consulting Services(Does not include medical services);Sales of Class I Medical Devices;Sales of Class II Medical Devices;Drug testing equipment sales;Technology Import and Export;Import and export;Chemical product sales(No licensed chemical products)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:pharmaceutical production;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Manufactures pharmaceuticals

Shanghai Pulmonary Hospital, a subsidiary of Tongji University, is a Chinese company located in Shanghai that provides medical services.